Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Crosses Above Two Hundred Day Moving Average of $3.44

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.44 and traded as high as $3.61. Brainstorm Cell Therapeutics shares last traded at $3.55, with a volume of 103,485 shares trading hands.

Separately, Dawson James reaffirmed a “neutral” rating on shares of Brainstorm Cell Therapeutics in a research report on Wednesday, December 22nd.

The company’s 50-day simple moving average is $3.50 and its 200 day simple moving average is $3.44. The stock has a market cap of $128.79 million, a P/E ratio of -4.03 and a beta of -0.09.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last posted its earnings results on Monday, November 15th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.06. During the same quarter in the prior year, the firm posted ($0.14) EPS. On average, research analysts predict that Brainstorm Cell Therapeutics Inc. will post -0.7 EPS for the current year.

Several hedge funds have recently modified their holdings of BCLI. Millennium Management LLC purchased a new stake in shares of Brainstorm Cell Therapeutics during the 2nd quarter worth approximately $1,412,000. Ergoteles LLC purchased a new position in Brainstorm Cell Therapeutics in the 2nd quarter valued at approximately $472,000. GSA Capital Partners LLP grew its stake in Brainstorm Cell Therapeutics by 185.6% in the 3rd quarter. GSA Capital Partners LLP now owns 172,056 shares of the biotechnology company’s stock valued at $568,000 after buying an additional 111,818 shares in the last quarter. Tibra Equities Europe Ltd purchased a new position in Brainstorm Cell Therapeutics in the 2nd quarter valued at approximately $331,000. Finally, Vanguard Group Inc. grew its stake in Brainstorm Cell Therapeutics by 6.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,412,826 shares of the biotechnology company’s stock valued at $5,369,000 after buying an additional 82,374 shares in the last quarter. Institutional investors own 14.15% of the company’s stock.

About Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Brainstorm Cell Therapeutics, Inc operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson’s disease, multiple sclerosis and spinal cord injury.

Recommended Story: Upside/Downside Explained

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.